New US risk class for human dura mater
This article was originally published in Clinica
Executive Summary
The US FDA has announced that human dura mater has been categorised as a class II product subject to special controls. As a result, companies wishing to sell the human material to repair defects in human dura mater will need to comply with a new guidance when they submit their 510(k)s. The guidance recommends clinical and histopathological methods, such as next of kin interviews and full brain autopsy intended to identify and defer potential donors who have vCJD/CJD.
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.